Clinical trials: Genitourinary Cancer
Superficial Bladder Cancer
Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer
The aim of this phase Ib/IIa study is to investigate the maximum tolerable concentration of abnobaVISCUM® Fraxini for intravesical instillation in patients with superficial bladder cancer.
- Trial name
- NCT02007005
- Testing
- abnobaVISCUM Fraxini
- Where
- 2 sites in Egypt, Germany
- Volunteers
- 37 people
- Sponsor
- Abnoba Gmbh
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
This is a Phase 1 study during which patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer will receive investigational study drug MEK162 and paclitaxel.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT01649336
- Testing
- MEK162, MEK inhibitor; oral, Paclitaxel, mitotic inhibitor; intravenous
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Advanced Cancer
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and Eph families.
- Trial name
- NCT02219711
- Testing
- MGCD516
- Where
- 43 sites in United States, South Korea
- Volunteers
- 193 people
- Sponsor
- Mirati Therapeutics Inc.
Solid Tumor, Microsatellite Stable Colorectal Cancer
Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
To determine the recommended Phase 2 dose (RP2D) of TBio-6517 when administered by direct injection into tumor(s) or intravenously and when combined with pembrolizumab in patients with solid tumors (RIVAL-01).
- Conditions
- Solid Tumor, Microsatellite Stable Colorectal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Cervical Cancer
- Trial name
- RAPTOR (NCT04301011)
- Testing
- TBio-6517, Pembrolizumab
- Where
- 11 sites in United States, Canada and 1 more
- Volunteers
- 27 people
- Sponsor
- Turnstone Biologics, Corp.
Platinum-resistant Ovarian Cancer, Endometrial Cancer
A Study of DeTIL-0255 in Adults With Advanced Malignancies
This is a first-in-human Phase 1 multicenter, open-label oncology study designed to evaluate the safety and efficacy of NX-DeTIL-0255-201 in patients with advanced malignancies.
- Conditions
- Platinum-resistant Ovarian Cancer, Endometrial Cancer, Cervical Cancer
- Trial name
- NCT05107739
- Testing
- Drug Product De-TIL-0255
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Nurix Therapeutics, Inc.
mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
This is a Phase 1/2, open-label, randomized, dose finding and dose expansion study to evaluate the safety, preliminary efficacy, and PK of gedatolisib in combination with darolutamide in subjects with mCRPC.
- Conditions
- mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male, Urogenital Diseases, Male, Prostatic Disease
- Trial name
- NCT06190899
- Testing
- Gedatolisib, Darolutamide
- Where
- 13 sites in United States, France and 2 more
- Volunteers
- 54 people
- Sponsor
- Celcuity Inc
Bladder Cancer
Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00006034
- Testing
- keyhole limpet hemocyanin, doxorubicin hydrochloride
- Where
- United States
- Sponsor
- Intracel
Advanced or Metastatic Solid Tumors, Ovarian Cancer
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
This research study is studying a new drug, NC410, as a possible treatment for advanced or metastatic solid tumors.
- Conditions
- Advanced or Metastatic Solid Tumors, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer
- Trial name
- NCT04408599
- Testing
- NC410
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- NextCure, Inc.
Prostatic Cancer
Quinacrine Treatment in Patients With Androgen-Independent Prostate Cancer
The purpose of this study is to determine whether quinacrine is effective in the treatment of Androgen-Independent Prostate Cancer.
- Trial name
- NCT00417274
- Testing
- Quinacrine
- Volunteers
- 31 people
- Sponsor
- Cleveland BioLabs
Neoplasm, Ovarian, Fallopian Tube Cancer
A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary
This is an open-label, First-in-Human, Phase 1/2, multicenter study to evaluate the safety and efficacy of a single dose of AVB-001.
- Conditions
- Neoplasm, Ovarian, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenocarcinoma Ovary
- Trial name
- NCT05538624
- Testing
- AVB-001 (Dose Escalation Phase), AVB-001 (Dose Expansion Phase)
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Avenge Bio, Inc
Glioblastoma
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
This is an event driven, adaptive design, a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 3 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent…
- Trial name
- NCT03149003
- Testing
- DSP-7888 Dosing Emulsion, Bevacizumab
- Where
- 61 sites in United States, Canada and 3 more
- Volunteers
- 221 people
- Sponsor
- Sumitomo Pharma America, Inc.
Urothelial Cancer
A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
Enfortumab vedotin (or PADCEV Injection) is a treatment for cancer in the bladder lining (urothelial cancer). PADCEV Injection is now available to treat this cancer.
- Trial name
- NCT06011954
- Testing
- Enfortumab Vedotin
- Where
- 22 sites in South Korea
- Volunteers
- 228 people
- Sponsor
- Astellas Pharma Korea, Inc.
Endometrial Cancer
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy…
- Trial name
- ASCENT-GYN-01 (NCT06486441)
- Testing
- Sacituzumab govitecan-hziy, Doxorubicin, Paclitaxel
- Where
- 189 sites in United States, Australia and 17 more
- Volunteers
- 640 people
- Sponsor
- Gilead Sciences
Cervical Cancer
AK104 in Neoadjuvant Treatment of Cervical Cancer
Phase II open label study to evaluate the safety and efficacy of AK104 (anti-PD-1 and CTLA-4 bispecific antibody) in neoadjuvant treatment of cervical cancer.
- Trial name
- NCT05227651
- Testing
- AK104
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Akeso
Hepatocellular Carcinoma, Prostate Cancer
LTFU for All Cell and Gene Therapy Studies
Master LTFU study will monitor the long-term safety and tolerability of cell or gene therapy study participants from AstraZeneca for up to 15 years post last cell or gene therapy treatment.
- Trial name
- LOCUS (NCT06194461)
- Testing
- AZD5851, AZD0754
- Where
- 25 sites in United States, Australia and 2 more
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Small Cell Lung Cancer, Melanoma
A Study of DXC014 in Patients With Advanced Solid Tumors.
This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC014 in patients with…
- Conditions
- Small Cell Lung Cancer, Melanoma, Prostate Cancer, Other Advanced Solid Tumors
- Trial name
- NCT07177937
- Testing
- DXC014
- Where
- 5 sites in China
- Volunteers
- 150 people
- Sponsor
- Hangzhou DAC Biotechnology Co., Ltd.
Prostate Cancer
Open Label Prostate Cancer Study
The main purpose of the study is to investigate the safety and tolerability of AZD3514 when given orally to patients with castration-resistant prostate cancer (CRPC)
- Trial name
- NCT01162395
- Testing
- AZD3514
- Where
- 5 sites in United States, Netherlands and 1 more
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Breast Cancer, Colorectal Cancer
Detection of Cancer in Breath Samples by Trained Detection Dogs
The goal of this study is to show that trained detection dogs can identify breast, lung, prostate or colorectal cancer by sniffing masks containing breath samples.
- Conditions
- Breast Cancer, Colorectal Cancer, PROSTATE CANCER, Lung Cancer
- Trial name
- NCT06255041
- Where
- 2 sites in Israel
- Volunteers
- 1,386 people, healthy volunteers welcome
- Sponsor
- SpotitEarly
Prostate Cancer
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as [177Lu]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter…
- Trial name
- NCT05803941
- Testing
- AAA617
- Where
- 54 sites in United States, Austria and 9 more
- Volunteers
- 700 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Neoplasms
A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate the effects of multiple doses of abiraterone acetate plus prednisone on the pharmacokinetics (study of what the body does to a drug) of single doses of dextromethorphan hydrobromide and…
- Trial name
- NCT01017939
- Testing
- Abiraterone acetate, Prednisone, Dextromethorphan hydrobromide
- Where
- 6 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Janssen Research & Development, LLC